Skip to main content

CSL Limited Marks 25 Years on the Australian Securities Exchange

Leaders ring the opening bell in Sydney and reflect on the company’s transformation into a global biotechnology business.

CSL CEO Paul Perreault and Brian McNamee at ASX anniversary

On Monday, CSL Limited, celebrated its 25th anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

CSL Behring, with global headquarters in King of Prussia, Pennsylvania, is a business of global biotechnology leader CSL Limited.

In 1994, the issued share price for CSL was $2.30 and for the 25 years that followed, the stock enjoyed a compound average growth rate of 25.2% per year.

“Staying true to our values has paid dividends for the business, our investors and the people that have benefited from the therapies we make. Many of our shareholders have had a long relationship with us and been able to share in the Company’s success,” said Dr. Brian McNamee, CSL Chairman.

CSL Limited CEO and Managing Director Paul Perreault said, “While the Company has evolved over the past 25 years, the one constant remains our commitment to delivering on our promise to patients and protecting public health around the world. Every day, our 25,000-plus employees are driven by our ability to improve the quality of people’s lives in nearly 70 countries.”